<DOC>
	<DOCNO>NCT00749801</DOCNO>
	<brief_summary>Nattokinase , first find Dr. Hiroyuki Sumi 1980 , potent fibrinolytic enzyme extract Natto , popular soybean ferment food Japan . It confirm oral administration nattokinase ( natto ) produce mild frequent enhancement fibrinolytic activity plasma indicate fibrinolytic parameter production tissue plasminogen activator . Other study also show reduction lipid peroxidation improvement lipid metabolism . Short-term effect ( le 10 day ) oral administration nattokinase animal human subject study report . However , whether nattokinase posse beneficial effect dyslipidemic patient remain unclear . The aim study investigate long-term effect ( six month ) mono multiple formulae nattokinase , change BP , lipid fibrinolytic factor baseline 6 month dyslipidemic patient .</brief_summary>
	<brief_title>Efficacy Safety Geneferm Nattokinase</brief_title>
	<detailed_description>This study employ randomize , double-blind , placebo-controlled , parallel-group design . Adult men woman meet inclusion/exclusion criterion give consent participate randomly assign one three group : Group A : nattokinase-mono formula ( 18 subject ) ; Group B : nattokinase compound ( multiple formula ) ( 18 subject ) ; Group C : placebo ( 10 subject ) . Laboratory test , include TG , total cholesterol , LDL-C , HDL-C , fibrinogen , D-Dimer , uric acid , vital sign body weight evaluated screening visit , 1 month , 3 month , 6 month visit initiation treatment . Vital sign body weight measure every visit . Patient self-evaluation tolerance physical improvement assess Patient Questionnaire visit . Each patient carefully monitor development adverse event ( AE ) . The change lab test vital sign plot compare time . Wilcoxon Signed-Rank test perform compare baseline 6 month initiation administration . Change baseline lab vital evaluation compare among three group Analysis Variance ( ANOVA ) follow LSD multiple comparison .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>1 . Men nonpregnant woman 40 year age . 2 . Dyslipidemic currently untreated lipidlowering drug . Dyslipidemia define : Total cholesterol 200~300 mg/dl ; Triglyceride 200~500 mg/dl ; Low density lipoproteincholesterol 130~200 mg/dl ; High density lipoprotein cholesterol &lt; 40 mg/dl ( male ) &lt; 50 mg/dl ( female ) . 3 . Subjects , opinion Investigator , able comply requirement study . 4 . Subjects adequately informed nature risk study give write informed consent prior receive investigational product . 1 . Receipt lipidlowering drug device within 12 week . 2 . Myocardial infarction within precede 12 week . 3 . Recent major trauma ( within 12 week ) . 4 . Recent surgery require anesthesia include coronary artery bypass graft ( within 12 week ) . 5 . Recent hospitalization ( within 12 week ) . 6 . Acute infection require current antibiotic therapy . 7 . Recent abrupt change ( within 1 month ) usual diet . 8 . Unstable medical condition life expectancy le 6 month . 9 . Known allergy component study product . 10 . Patients acute disease , opinion investigator , suitable participate study . 11 . Total cholesterol &gt; 300 mg/dl ; Triglyceride &gt; 500 mg/dl ; Low density lipoproteincholesterol &gt; 200 mg/dl . 12 . Current use warfarin .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>drug naive</keyword>
	<keyword>Dyslipidemic</keyword>
	<keyword>nattokinase</keyword>
	<keyword>fibrinolytic</keyword>
</DOC>